LENSAR Inc (NASDAQ: LNSR) is a Healthcare company (Medical - Devices) with a market capitalization of $60M. The Maz Rating grades it against the other companies in its sector.
LENSAR Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $4.91, LENSAR Inc trades at 4.2x trailing earnings, 1.0x sales and 5.6x book value, with an EV/EBITDA of 1.4. Over the last twelve months it generated about $59M of revenue and $14M of net income. It runs a gross margin of 52.0%, an operating margin of -3.3% and a net margin of 56.1%. It shows return on equity of 549.4%, return on invested capital of -4.1% and a free cash flow yield of -7.9%. On the balance sheet: a debt-to-equity ratio of 0.20 and a current ratio of 2.25. Over the past 52 weeks the share price ranged from $4.30 to $12.94, with a beta of 1.03.
LENSAR Inc does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 2 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, LENSAR Inc (LNSR) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 15.0% / 30% · Interest income / Revenue 0.13% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.0% / 33% · Receivables / Mkt Cap (36m) 6.69% / 49% · Interest income / Revenue 0.13% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.0% / 33.33% · Receivables / Mkt Cap (24m) 6.69% / 33.33% · Interest income / Revenue 0.13% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.29% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 21.0% / 33.33% · Receivables / Avg Assets (4Q) 8.70% / 33.33% · Interest income / Revenue 0.13% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 18.8% / 33.33% · (Cash+Recv) / Total Assets 27.2% / 33.33% · Interest income / Revenue 0.13% / 5% | Pass |
Yes. As of September 2026, LENSAR Inc (LNSR) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. LENSAR Inc is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.13% of each dividend: LENSAR Inc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.